PIN1 and hepatocellular carcinoma: In summary, our results have shown for the fist time that targeting Pin1 offers a promising therapeutic approach to simultaneously stop multiple cancer-driving pathways in HCC, further providing a rationale for developing longer half-life ATRA or more potent and specific Pin1-targeted ATRA derivatives to overcome drug resistance in treating aggressive cancers such as HCC.